← Back to Clinical Trials
Recruiting NCT06458322

NCT06458322 Quality of Life in Patients Transitioning to Home or In-Center Dialysis (QUALIFY CKD-to-HOME)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06458322
Status Recruiting
Phase
Sponsor Ciusss de L'Est de l'Île de Montréal
Condition Chronic Kidney Diseases
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2022-07-01
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Home dialysis or In-Center dialysis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2022-07-01 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to evaluate quality of life (QoL) and frailty trajectories from advanced chronic kidney disease (CKD) to after dialysis initiation, specifically comparing patients choosing home dialysis and in-center hemodialysis. The main questions it aims to answer are: 1. What is the trajectory of QoL in patients transitioning from advanced CKD to dialysis (up to 12 months after initiation) and how does these changes differ for patients oriented towards home dialysis and in-center hemodialysis? 2. Is the development of frailty after dialysis initiation less likely in patient pursuing home dialysis? 3. What is the variation in other PROMs and health outcomes (fatigue, anxiety \& depression, general assessment, cognitive function) form advanced CKD to the first 12 months after dialysis initiation? 4. What are the predictors of severe decline in QoL, frailty and other important health outcomes (fatigue, cognition, anxiety \& depression) during CKD G5 follow-up and after 12 months post dialysis initiation? Participants will be ask to: * Answer some questions and complete questionnaires each 3 months; * Do a a grip test and a walking test each 6 months to evaluate their frailty;

Eligibility Criteria

Inclusion Criteria: * Adult patients followed in advanced CKD clinic; * eGFR ≤12 mL/min/1.73m2 96; * Understand English or French. Exclusion Criteria: * Orientation toward conservative treatment; * Planned kidney transplantation \< 6 months; * Unable to provide consent due to severe cognitive or psychiatric disease; * Previous treatment with dialysis \> 3 month; * Life expectancy \< 6 months.

Contact & Investigator

Central Contact

Émilie Robitaille, Bac Sc. Inf.

✉ emilie.robitaille.cemtl@ssss.gouv.qc.ca

📞 514-252-3400

Principal Investigator

Annie-Claire Nadeau-Fredette, MD

PRINCIPAL INVESTIGATOR

Ciusss de L'Est de l'Île de Montréal

Frequently Asked Questions

Who can join the NCT06458322 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06458322 currently recruiting?

Yes, NCT06458322 is actively recruiting participants. Contact the research team at emilie.robitaille.cemtl@ssss.gouv.qc.ca for enrollment information.

Where is the NCT06458322 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT06458322 clinical trial?

NCT06458322 is sponsored by Ciusss de L'Est de l'Île de Montréal. The principal investigator is Annie-Claire Nadeau-Fredette, MD at Ciusss de L'Est de l'Île de Montréal. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology